FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Mark Ratain

Research Profile

Disorders

Chemicals & Drugs

Concepts & Ideas

Procedures

Co-author Network

Publications

TOP 3
Michael L Maitland; Mark J Ratain; M R Sharma; W M Stadler; K Wu; Y Jin; Soonmo Peter Kang; T G Karrison; R R Bies
Estimation of renal cell carcinoma treatment effects from disease progression modeling.
R Z Szmulewitz; Mark J Ratain
Playing Russian roulette with tyrosine kinase inhibitors.
Michael J Seminerio; Mark J Ratain
Preventing adverse drug-drug interactions: a need for improved data and logistics.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Mark Ratain (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Michael L Maitland; Mark J Ratain; M R Sharma; W M Stadler; K Wu; Y Jin; Soonmo Peter Kang; T G Karrison; R R Bies
Estimation of renal cell carcinoma treatment effects from disease progression modeling.
Clinical pharmacology and therapeutics 2013;93(4):345-51.
2013: R Z Szmulewitz; Mark J Ratain
Playing Russian roulette with tyrosine kinase inhibitors.
Clinical pharmacology and therapeutics 2013;93(3):242-4.
2013: Michael J Seminerio; Mark J Ratain
Preventing adverse drug-drug interactions: a need for improved data and logistics.
Mayo Clinic proceedings. Mayo Clinic 2013;88(2):126-8.
2013: Heather E Wheeler; Eric P Winer; Claudia Wing; Hitoshi Zembutsu; Robert Michael Baldwin; Nancy J Cox; Eric Gamazon; Clifford A Hudis; Chen Jiang; Deanna L Kroetz; Michiaki Kubo; Yusuke Nakamura; Uchenna O Njiaju; Chidiamara Njoku; Kouros Owzar; Mark J Ratain; Ivo Shterev; Lawrence N Shulman; Dorothy Watson; Mary Eileen Dolan
Integration of cell line and clinical trial genome-wide analyses supports a polygenic architecture of Paclitaxel-induced sensory peripheral neuropathy.
Clinical cancer research : an official journal of the American Association for Cancer Research 2013;19(2):491-9.
2013: Shiro Kitano; Wanqing Liu; Jamie Myers; Junko Nakamura; Masato Nakayama; Mark J Ratain; Yusuke Tsukahara; Hiroshi Ushida; Akio Yamane; Mami Yamashita; Masahiko Amano
A Novel Fully Automated Molecular Diagnostic System (AMDS) for Colorectal Cancer Mutation Detection.
PloS one 2013;8(5):e62989.
2013: Ling-Zhi Wang; Andrea Li-Ann Wong; Winnie Yeo; Ying Kiat Zee; Sherry Ansher; Anthony Chan; Mei-Yi Michelle Chan; Paul C Ho; Jie-Ying Amelia Lau; How-Sung Lee; Soo-Chin Lee; Robert Lim; Jacqueline Ramírez; Mark J Ratain; Win-Lwin Thuya; Seow-Ching Wan; Boon Cher Goh
Glucuronidation by UGT1A1 is the dominant pathway of the metabolic disposition of belinostat in liver cancer patients.
PloS one 2013;8(1):e54522.
2013: Lionel D Lewis; Svetlana Markova; Howard L McLeod; Antonius A Miller; Kouros Owzar; Mark J Ratain; Robert R Bies; Merrill J Egorin; Chen Jiang; Deanna L Kroetz
The relationship of polymorphisms in ABCC2 and SLCO1B3 with docetaxel pharmacokinetics and neutropenia: CALGB 60805 (Alliance).
Pharmacogenetics and genomics 2013;23(1):29-33.
2013: Heather E Wheeler; Nancy J Cox; M Eileen Dolan; Michael L Maitland; Mark J Ratain
Cancer pharmacogenomics: strategies and challenges.
Nature reviews. Genetics 2013;14(1):23-34.
2012: M R Sharma; Michael L Maitland; Mark J Ratain
Models of excellence: improving oncology drug development.
Clinical pharmacology and therapeutics 2012;92(5):548-50.
2012: Manish R Sharma; Michael L Maitland; Mark J Ratain
Why RECIST works and why it should stay--reply to counterpoint.
Cancer research 2012;72(20):5158.
2012: Manish R Sharma; Michael L Maitland; Mark J Ratain
RECIST: no longer the sharpest tool in the oncology clinical trials toolbox---point.
Cancer research 2012;72(20):5145-9; discussion 5150.
2012: P H O'Donnell; D Saner; J Spitz; A Bush; Nancy J Cox; K Danahey; S Das; Mark J Ratain
The 1200 patients project: creating a new medical model system for clinical implementation of pharmacogenomics.
Clinical pharmacology and therapeutics 2012;92(4):446-9.
2012: Kathleen M Giacomini; Naoyuki Kamatani; Mark J Ratain; Richard M Weinshilboum; Sook Wah Yee; Yusuke Nakamura
Pharmacogenomics and patient care: one size does not fit all.
Science translational medicine 2012;4(153):153ps18.
2012: R Michael Baldwin; Aparna Chhibber; Rachel J Eclov; Paula N Friedman; Clifford A Hudis; Chen Jiang; Eric Jorgenson; Michiaki Kubo; Howard L McLeod; Joel Mefford; Yusuke Nakamura; Kouros Owzar; Mark J Ratain; Lawrence N Shulman; Dorothy Watson; Eric P Winer; John S Witte; Hitoshi Zembutsu; Deanna L Kroetz
A genome-wide association study identifies novel loci for paclitaxel-induced sensory peripheral neuropathy in CALGB 40101.
Clinical cancer research : an official journal of the American Association for Cancer Research 2012;18(18):5099-109.
2012: Ezra E W Cohen; Kimberly Napoli Eaton; Gini F Fleming; Kammi Fox-Kay; Thomas F Gajewski; Christine Hartford; Larry House; Masha Kocherginsky; Michael L Maitland; Kristin Moshier; Anitha Nallari; Jacqueline Ramirez; Samir D Undevia; Kehua Wu; Yuanyuan Zha; Mark J Ratain
Phase I studies of sirolimus alone or in combination with pharmacokinetic modulators in advanced cancer patients.
Clinical cancer research : an official journal of the American Association for Cancer Research 2012;18(17):4785-93.
2012: Yusuke Nakamura; Mark J Ratain; Nancy J Cox; Deanna L Kroetz; Howard L McLeod; David A Flockhart
Re: CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the Breast International Group 1-98 trial.
Journal of the National Cancer Institute 2012;104(16):1264; author reply 1266-8.
2012: Lionel D Lewis; Mark J Ratain
Might cigarettes be a "smoking gun" to reduce taxane myelotoxicity?
Clinical cancer research : an official journal of the American Association for Cancer Research 2012;18(16):4219-21.
2012: Mark J Ratain
Importance of food effects for oral oncology drugs.
Clinical advances in hematology & oncology : H&O 2012;10(6):397-8.
2012: Manish R Sharma; Walter M Stadler; Robert R Bies; Yuyan Jin; Theodore G Karrison; Michael L Maitland; Mark J Ratain
Resampling phase III data to assess phase II trial designs and endpoints.
Clinical cancer research : an official journal of the American Association for Cancer Research 2012;18(8):2309-15.
2012: Peter H O'Donnell; Mark J Ratain
Germline pharmacogenomics in oncology: decoding the patient for targeting therapy.
Molecular oncology 2012;6(2):251-9.
2012: Peter H O'Donnell; Linda Janisch; Theodore M Karrison; M Kelly Nicholas; Walter M Stadler; Samir D Undevia; Mark J Ratain
A phase I study of continuous infusion cilengitide in patients with solid tumors.
Investigational new drugs 2012;30(2):604-10.
2012: Federico Innocenti; Chen Jiang; Hedy L Kindler; Michiaki Kubo; Liang Li; Howard L McLeod; Taisei Mushiroda; Yusuke Nakamura; Kouros Owzar; Nancy L Cox; Patrick Evans; Paula Friedman; Kathleen M Giacomini; Dylan Glubb; Richard M Goldberg; Donna Hollis; Herbert Hurwitz; Richard L Schilsky; Liewei Wang; Hitoshi Zembutsu; Mark J Ratain
A genome-wide association study of overall survival in pancreatic cancer patients treated with gemcitabine in CALGB 80303.
Clinical cancer research : an official journal of the American Association for Cancer Research 2012;18(2):577-84.
2012: Jonas A de Souza; Neal J Meropol; Lee N Newcomer; Monica Perkins; Blase Polite; Mark J Ratain; G Caleb Alexander
Unsupported off-label chemotherapy in metastatic colon cancer.
BMC health services research 2012;12():481.
2011: Jacqueline Ramírez; Kehua Wu; Ezra E W Cohen; Larry K House; Federico Innocenti; Linda Janisch; Theodore Karrison; Mark J Ratain
The effect of thalidomide on the pharmacokinetics of irinotecan and metabolites in advanced solid tumor patients.
Cancer chemotherapy and pharmacology 2011;68(6):1629-32.
2011: Mark J Ratain
Flushing oral oncology drugs down the toilet.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2011;29(30):3958-9.
2011: Adam Feuerstein; Mark J Ratain
Oncology micro-cap stocks: caveat emptor!
Journal of the National Cancer Institute 2011;103(20):1488-9.
2011: Rachel W Humphrey; Kathleen M Dohoney; James H Doroshow; Sandra J Meech; Mark J Ratain; Suzanne Topalian; David T Bonk; Laura M Brockway-Lunardi; Drew M Pardoll
Opportunities and challenges in the development of experimental drug combinations for cancer.
Journal of the National Cancer Institute 2011;103(16):1222-6.
2011: Manish R Sharma; Walter M Stadler; Mark J Ratain
Randomized phase II trials: a long-term investment with promising returns.
Journal of the National Cancer Institute 2011;103(14):1093-100.
2011: Razelle Kurzrock; Ranee Mehra; Thomas Müller; Forlisa Nauling; Chaan S Ng; David G Pfister; Mark J Ratain; Douglas W Ball; Ezra E W Cohen; Roger B Cohen; Arlene A Forastiere; John Frye; Robert F Gagel; David S Hong; Linda Janisch; Steven I Sherman; Lei Ye; Ravi Salgia
Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2011;29(19):2660-6.
2011: E E W Cohen; Gini F Fleming; L House; Linda Janisch; M Llobrera; Jacqueline Ramirez; M R Sharma; Walter M Stadler; K Wu; Mark J Ratain
A phase I study of sirolimus and bevacizumab in patients with advanced malignancies.
European journal of cancer (Oxford, England : 1990) 2011;47(10):1484-9.
2011: Yong Liu; Jacqueline Ramírez; Mark J Ratain
Inhibition of paracetamol glucuronidation by tyrosine kinase inhibitors.
British journal of clinical pharmacology 2011;71(6):917-20.
2011: Simon Pacey; Mark J Ratain; Keith T Flaherty; Stanley B Kaye; Lisa Cupit; Eric K Rowinsky; Chenghua Xia; Peter J O'Dwyer; I R Judson
Efficacy and safety of sorafenib in a subset of patients with advanced soft tissue sarcoma from a Phase II randomized discontinuation trial.
Investigational new drugs 2011;29(3):481-8.
2011: Federico Innocenti; Gregory M Cooper; Ian B Stanaway; Eric Gamazon; Joshua D Smith; Snezana Mirkov; Jacqueline Ramirez; Wanqing Liu; Yvonne S Lin; Cliona Moloney; Shelly Force Aldred; Nathan D Trinklein; Erin G Schuetz; Deborah A Nickerson; Ken E Thummel; Mark J Rieder; Allan E Rettie; Mark J Ratain; Nancy J Cox; Christopher D Brown
Identification, replication, and functional fine-mapping of expression quantitative trait loci in primary human liver tissue.
PLoS genetics 2011;7(5):e1002078.
2011: Jonas A de Souza; Blase N Polite; Willard G Manning; A Mark Fendrick; Mark J Ratain
Value-based insurance design in oncology.
The lancet oncology 2011;12(4):321-3.
2011: Tara C Gangadhar; Ezra E W Cohen; Kehua Wu; Linda Janisch; David Geary; Masha Kocherginsky; Larry K House; Jackie Ramirez; Samir D Undevia; Michael L Maitland; Gini F Fleming; Mark J Ratain
Two drug interaction studies of sirolimus in combination with sorafenib or sunitinib in patients with advanced malignancies.
Clinical cancer research : an official journal of the American Association for Cancer Research 2011;17(7):1956-63.
2011: Wanqing Liu; Lijun He; Jacqueline Ramírez; Soundararajan Krishnaswamy; Rajani Kanteti; Yi-Ching Wang; Ravi Salgia; Mark J Ratain
Functional EGFR germline polymorphisms may confer risk for EGFR somatic mutations in non-small cell lung cancer, with a predominant effect on exon 19 microdeletions.
Cancer research 2011;71(7):2423-7.
2011: Mark J Ratain
Current dilemmas in carboplatin dosing.
Clinical advances in hematology & oncology : H&O 2011;9(3):237-8.
2011: Mark J Ratain; J M Collins; James Doroshow
Merrill Jon Egorin, MD, 1948-2010.
Clinical pharmacology and therapeutics 2011;89(2):163-5.
2011: Russ B Altman; Heyo K Kroemer; Catherine A McCarty; Mark J Ratain; Dan Roden
Pharmacogenomics: will the promise be fulfilled?
Nature reviews. Genetics 2011;12(1):69-73.
2010: Landry K Kamdem; Yong Liu; Vered Stearns; Susan A Kadlubar; Jacqueline Ramirez; Stacie Jeter; Karineh Shahverdi; Bryan A Ward; Evan Ogburn; Mark J Ratain; David A Flockhart; Zeruesenay Desta
In vitro and in vivo oxidative metabolism and glucuronidation of anastrozole.
British journal of clinical pharmacology 2010;70(6):854-69.
2010: Andrew N Freedman; Leah B Sansbury; William D Figg; Arnold L Potosky; Sheila Weiss Smith; Muin J Khoury; Stefanie A Nelson; Richard M Weinshilboum; Mark J Ratain; Howard L McLeod; Robert S Epstein; Geoffrey S Ginsburg; Richard L Schilsky; Geoffrey Liu; David A Flockhart; Cornelia M Ulrich; Robert L Davis; Lawrence J Lesko; Issam Zineh; Gurvaneet Randhawa; Christine B Ambrosone; Mary V Relling; Nat Rothman; Heng Xie; Margaret R Spitz; Rachel Ballard-Barbash; James H Doroshow; Lori M Minasian
Cancer pharmacogenomics and pharmacoepidemiology: setting a research agenda to accelerate translation.
Journal of the National Cancer Institute 2010;102(22):1698-705.
2010: Michael L Maitland; Christine Hudoba; Kelly L Snider; Mark J Ratain
Analysis of the yield of phase II combination therapy trials in medical oncology.
Clinical cancer research : an official journal of the American Association for Cancer Research 2010;16(21):5296-302.
2010: Paul Hamberg; Mark J Ratain; Emmanuel Lesaffre; Jaap Verweij
Dose-escalation models for combination phase I trials in oncology.
European journal of cancer (Oxford, England : 1990) 2010;46(16):2870-8.
2010: Soonmo Peter Kang; Jacqueline Ramirez; Larry House; Wei Zhang; Snezana Mirkov; Wanqing Liu; Eden Haverfield; Mark J Ratain
A pharmacogenetic study of vorinostat glucuronidation.
Pharmacogenetics and genomics 2010;20(10):638-41.
2010: Soonmo Peter Kang; Mark J Ratain
Inconsistent labeling of food effect for oral agents across therapeutic areas: differences between oncology and non-oncology products.
Clinical cancer research : an official journal of the American Association for Cancer Research 2010;16(17):4446-51.
2010: Yong Liu; Jacqueline Ramírez; Larry House; Mark J Ratain
The UGT1A1*28 polymorphism correlates with erlotinib's effect on SN-38 glucuronidation.
European journal of cancer (Oxford, England : 1990) 2010;46(11):2097-103.
2010: Mark J Ratain
Bar the windows but open the door to randomization.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(19):3104-6.
2010: Michael L Maitland; Xing Jian Lou; Jacqueline Ramirez; Apurva A Desai; Dorit S Berlin; Howard L McLeod; Ralph R Weichselbaum; Mark J Ratain; Russ B Altman; Teri E Klein
Vascular endothelial growth factor pathway.
Pharmacogenetics and genomics 2010;20(5):346-9.
2010: Jacqueline Ramírez; Mark J Ratain; Federico Innocenti
Uridine 5'-diphospho-glucuronosyltransferase genetic polymorphisms and response to cancer chemotherapy.
Future oncology (London, England) 2010;6(4):563-85.
2010: Janet E Dancey; Kevin K Dobbin; Susan Groshen; J Milburn Jessup; Andrew H Hruszkewycz; Maria Koehler; Ralph Parchment; Mark J Ratain; Lalitha K Shankar; Walter M Stadler; Lawrence True; Amy Gravell; Michael R Grever
Guidelines for the development and incorporation of biomarker studies in early clinical trials of novel agents.
Clinical cancer research : an official journal of the American Association for Cancer Research 2010;16(6):1745-55.
2010: Lesley Seymour; S Percy Ivy; Daniel Sargent; David Spriggs; Laurence H Baker; Larry Rubinstein; Mark J Ratain; Michael Le Blanc; David Stewart; John Crowley; Susan Groshen; Jeff Humphrey; Pamela West; Donald Berry
The design of phase II clinical trials testing cancer therapeutics: consensus recommendations from the clinical trial design task force of the national cancer institute investigational drug steering committee.
Clinical cancer research : an official journal of the American Association for Cancer Research 2010;16(6):1764-9.
2010: Mardi Gomberg-Maitland; Michael L Maitland; Robyn J Barst; L Sugeng; S Coslet; T J Perrino; L Bond; Mario Lacouture; S L Archer; Mark J Ratain
A dosing/cross-development study of the multikinase inhibitor sorafenib in patients with pulmonary arterial hypertension.
Clinical pharmacology and therapeutics 2010;87(3):303-10.
2010: Mark J Ratain; Federico Innocenti
Individualizing dosing of irinotecan.
Clinical cancer research : an official journal of the American Association for Cancer Research 2010;16(2):371-2.
2010: Yong Liu; Jacqueline Ramírez; Larry House; Mark J Ratain
Comparison of the drug-drug interactions potential of erlotinib and gefitinib via inhibition of UDP-glucuronosyltransferases.
Drug metabolism and disposition: the biological fate of chemicals 2010;38(1):32-9.
2009: Michael L Maitland; Kristen E Kasza; Theodore Karrison; Kristin Moshier; Laura Sit; Henry R Black; Samir D Undevia; Walter M Stadler; William J Elliott; Mark J Ratain
Ambulatory monitoring detects sorafenib-induced blood pressure elevations on the first day of treatment.
Clinical cancer research : an official journal of the American Association for Cancer Research 2009;15(19):6250-7.
2009: Manish R Sharma; Michael L Maitland; Mark J Ratain
Other paradigms: better treatments are identified by better trials: the value of randomized phase II studies.
Cancer journal (Sudbury, Mass.) 2009;15(5):426-30.
2009: Wei Zhang; Daniel V T Catenacci; Shiwei Duan; Mark J Ratain
A survey of the population genetic variation in the human kinome.
Journal of human genetics 2009;54(8):488-92.
2009: Janelle Hoskins; Gary Rosner; Mark J Ratain; howard mcleod; Federico Innocenti
Pharmacodynamic genes do not influence risk of neutropenia in cancer patients treated with moderately high-dose irinotecan.
Pharmacogenomics 2009;10(7):1139-46.
2009: Wei Peng Yong; Tae Won Kim; Samir D Undevia; Federico Innocenti; Mark J Ratain
R(+)XK469 inhibits hydroxylation of S-warfarin by CYP2C9.
European journal of cancer (Oxford, England : 1990) 2009;45(11):1904-8.
2009: Federico Innocenti; Deanna L Kroetz; Erin G Schuetz; M Eileen Dolan; Jacqueline Ramírez; Mary Relling; Peixian Chen; Soma Das; Gary Rosner; Mark J Ratain
Comprehensive pharmacogenetic analysis of irinotecan neutropenia and pharmacokinetics.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(16):2604-14.
2009: Antonius A Miller; Daryl J Murry; Kouros Owzar; Donna Hollis; Erin B Kennedy; Ghassan K Abou-Alfa; Apurva Desai; Jimmy Hwang; Miguel A Villalona-Calero; Elizabeth Dees; Lionel D Lewis; Marwan G Fakih; Martin J Edelman; Fred Millard; Richard C Frank; Raymond J Hohl; Mark J Ratain
Phase I and pharmacokinetic study of sorafenib in patients with hepatic or renal dysfunction: CALGB 60301.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(11):1800-5.
2009: Wei Zhang; Lijun He; Wanqing Liu; Chang Sun; Mark J Ratain
Exploring the relationship between polymorphic (TG/CA)n repeats in intron 1 regions and gene expression.
Human genomics 2009;3(3):236-45.
2009: Federico Innocenti; Snezana Mirkov; Ramamoorthy Nagasubramanian; Jacqueline Ramírez; Wanqing Liu; Wasim K Bleibel; Sunita J Shukla; Kathy Hennessy; Gary Rosner; Edwin H Cook; M Eileen Dolan; Mark J Ratain
The Werner's syndrome 4330T>C (Cys1367Arg) gene variant does not affect the in vitro cytotoxicity of topoisomerase inhibitors and platinum compounds.
Cancer chemotherapy and pharmacology 2009;63(5):881-7.
2009: Nancy L Bartlett; Jeffrey L Johnson; Nina Wagner-Johnston; Mark J Ratain; Bruce A Peterson
Phase II study of 9-aminocamptothecin in previously treated lymphomas: results of Cancer and Leukemia Group B 9551.
Cancer chemotherapy and pharmacology 2009;63(5):793-8.
2009: Christine M Hartford; Apurva A Desai; Linda Janisch; Theodore Karrison; Victor M Rivera; Lori Berk; John W Loewy; Hedy L Kindler; Walter M Stadler; Heather L Knowles; Camille Bedrosian; Mark J Ratain
A phase I trial to determine the safety, tolerability, and maximum tolerated dose of deforolimus in patients with advanced malignancies.
Clinical cancer research : an official journal of the American Association for Cancer Research 2009;15(4):1428-34.
2009: Minoli A Perera; R K Thirumaran; Nancy J Cox; Stephen B Hanauer; Soma Das; C Brimer-Cline; V Lamba; Erin G Schuetz; Mark J Ratain; Anna Di Rienzo
Prediction of CYP3A4 enzyme activity using haplotype tag SNPs in African Americans.
The pharmacogenomics journal 2009;9(1):49-60.
2009: R Stephanie Huang; Mark J Ratain
Pharmacogenetics and pharmacogenomics of anticancer agents.
CA: a cancer journal for clinicians 2009;59(1):42-55.
2009: Mark J Ratain; Daniel J Sargent
Optimising the design of phase II oncology trials: the importance of randomisation.
European journal of cancer (Oxford, England : 1990) 2009;45(2):275-80.
2008: Olwen M Hahn; Cheng Yang; Milica Medved; Gregory S Karczmar; Emily Kistner; Theodore Karrison; Elizabeth Manchen; Myrosia Mitchell; Mark J Ratain; Walter M Stadler
Dynamic contrast-enhanced magnetic resonance imaging pharmacodynamic biomarker study of sorafenib in metastatic renal carcinoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(28):4572-8.
2008: Wei Zhang; Wanqing Liu; Enrique Poradosu; Mark J Ratain
Genome-wide identification of genetic determinants for the cytotoxicity of perifosine.
Human genomics 2008;3(1):53-70.
2008: Gary Rosner; J C Panetta; F Innocenti; Mark J Ratain
Pharmacogenetic pathway analysis of irinotecan.
Clinical pharmacology and therapeutics 2008;84(3):393-402.
2008: Rena Conti; D O Meltzer; Mark J Ratain
Nonprofit biomedical companies.
Clinical pharmacology and therapeutics 2008;84(2):194-7.
2008: Samir D Undevia; Federico Innocenti; Jacqueline Ramirez; Larry House; Apurva A Desai; Linda A Skoog; Deepti A Singh; Theodore Karrison; Hedy L Kindler; Mark J Ratain
A phase I and pharmacokinetic study of the quinoxaline antitumour Agent R(+)XK469 in patients with advanced solid tumours.
European journal of cancer (Oxford, England : 1990) 2008;44(12):1684-92.
2008: Federico Innocenti; Wanqing Liu; Donna Fackenthal; Jacqueline Ramírez; Peixian Chen; Xin Ye; Xiaolin Wu; Wei Zhang; Snezana Mirkov; Soma Das; Edwin H Cook; Mark J Ratain
Single nucleotide polymorphism discovery and functional assessment of variation in the UDP-glucuronosyltransferase 2B7 gene.
Pharmacogenetics and genomics 2008;18(8):683-97.
2008: Wendy Stock; Samir D Undevia; Carol Bivins; Farhad Ravandi; Olatoyosi Odenike; Stefan Faderl; Elizabeth Rich; Gautam Borthakur; Lucy Godley; Srdan Verstovsek; Andrew Artz; William Wierda; Richard A Larson; Yanming Zhang; Jorge Cortes; Mark J Ratain; Francis Giles
A phase I and pharmacokinetic study of XK469R (NSC 698215), a quinoxaline phenoxypropionic acid derivative, in patients with refractory acute leukemia.
Investigational new drugs 2008;26(4):331-8.
2008: Scott Weiss; howard mcleod; David A Flockhart; M Eileen Dolan; Neal L Benowitz; Julie A Johnson; Mark J Ratain; Kathleen M Giacomini
Creating and evaluating genetic tests predictive of drug response.
Nature reviews. Drug discovery 2008;7(7):568-74.
2008: Minoli A Perera; Federico Innocenti; Mark J Ratain
Pharmacogenetic testing for uridine diphosphate glucuronosyltransferase 1A1 polymorphisms: are we there yet?
Pharmacotherapy 2008;28(6):755-68.
2008: Olatoyosi Odenike; Richard A Larson; Devika Gajria; M Eileen Dolan; Shannon M Delaney; Theodore Karrison; Mark J Ratain; Wendy Stock
Phase I study of the ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehyde-thiosemicarbazone (3-AP) in combination with high dose cytarabine in patients with advanced myeloid leukemia.
Investigational new drugs 2008;26(3):233-9.
2008: Liliana Moreno Vinasco; Mardi Gomberg-Maitland; Michael L Maitland; Apurva A Desai; Patrick A Singleton; Saad Sammani; Lee Sam; Yang Liu; Aliya N Husain; Roberto M Lang; Mark J Ratain; Yves lussier; Joe G. N. Garcia
Genomic assessment of a multikinase inhibitor, sorafenib, in a rodent model of pulmonary hypertension.
Physiological genomics 2008;33(2):278-91.
2008: Jacqueline Ramírez; Snezana Mirkov; Wei Zhang; Peixian Chen; Soma Das; Wanqing Liu; Mark J Ratain; Federico Innocenti
Hepatocyte nuclear factor-1 alpha is associated with UGT1A1, UGT1A9 and UGT2B7 mRNA expression in human liver.
The pharmacogenomics journal 2008;8(2):152-61.
2008: Christopher K Daugherty; Mark J Ratain; Ezekiel J Emanuel; Ann T Farrell; Richard L Schilsky
Ethical, scientific, and regulatory perspectives regarding the use of placebos in cancer clinical trials.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(8):1371-8.
2008: Charles Rudin; Wanqing Liu; Apurva Desai; Theodore Karrison; Xuemin Jiang; Linda Janisch; Soma Das; Jacqueline Ramirez; Balasubramanian Poonkuzhali; Erin G Schuetz; Donna Lee Fackenthal; Peixian Chen; Deborah K Armstrong; Julie R Brahmer; Gini F Fleming; Everett E Vokes; Michael A Carducci; Mark J Ratain
Pharmacogenomic and pharmacokinetic determinants of erlotinib toxicity.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(7):1119-27.
2008: Wei Zhang; Mark J Ratain; M Eileen Dolan
The HapMap Resource is Providing New Insights into Ourselves and its Application to Pharmacogenomics.
Bioinformatics and biology insights 2008;2():15-23.
2008: Mark J Ratain; Rachel W Humphrey; Gary B Gordon; Gwen Fyfe; Peter Charles Adamson; Thomas R Fleming; Walter M Stadler; Donald A Berry; Carl C Peck
Recommended changes to oncology clinical trial design: revolution or evolution?
European journal of cancer (Oxford, England : 1990) 2008;44(1):8-11.
2007: Jacqueline Ramírez; Wanqing Liu; Snezana Mirkov; Apurva A Desai; Peixian Chen; Soma Das; Federico Innocenti; Mark J Ratain
Lack of association between common polymorphisms in UGT1A9 and gene expression and activity.
Drug metabolism and disposition: the biological fate of chemicals 2007;35(12):2149-53.
2007: Wanqing Liu; Xiaolin Wu; Wei Zhang; Raquel C Montenegro; Donna Lee Fackenthal; Jared A Spitz; Lyn Mickley Huff; Federico Innocenti; Soma Das; Edwin H Cook; Nancy J Cox; Susan E Bates; Mark J Ratain
Relationship of EGFR mutations, expression, amplification, and polymorphisms to epidermal growth factor receptor inhibitors in the NCI60 cell lines.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(22 Pt 1):6788-95.
2007: Mark J Ratain; Robert H Glassman
Biomarkers in phase I oncology trials: signal, noise, or expensive distraction?
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(22 Pt 1):6545-8.
2007: Bruce A Chabner; Mark J Ratain
Clarification regarding "phase II trials published in 2002: a cross-specialty comparison showing significant design differences between oncology trials and other medical specialties" and the accompanying commentary, "phase II cancer trials: out of control?".
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(21):6540.
2007: Wei Peng Yong; Apurva A Desai; Federico Innocenti; Jacqueline Ramirez; Dale R Shepard; Ken Kobayashi; Larry House; Gini F Fleming; Nicholas J Vogelzang; Richard L Schilsky; Mark J Ratain
Pharmacokinetic modulation of oral etoposide by ketoconazole in patients with advanced cancer.
Cancer chemotherapy and pharmacology 2007;60(6):811-9.
2007: Michael L Maitland; Mark J Ratain; Nancy J Cox
Interpreting P values in pharmacogenetic studies: a call for process and perspective.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(29):4513-5.
2007: Theodore Karrison; Michael L Maitland; Walter M Stadler; Mark J Ratain
Design of phase II cancer trials using a continuous endpoint of change in tumor size: application to a study of sorafenib and erlotinib in non small-cell lung cancer.
Journal of the National Cancer Institute 2007;99(19):1455-61.
2007: Mark J Ratain
The investigational drug steering committee.
Clinical advances in hematology & oncology : H&O 2007;5(10):779-80.
2007: C M Hartford; Mark J Ratain
Rapamycin: something old, something new, sometimes borrowed and now renewed.
Clinical pharmacology and therapeutics 2007;82(4):381-8.
2007: Stacy W Gray; Fay J Hlubocky; Mark J Ratain; Christopher K Daugherty
Attitudes toward research participation and investigator conflicts of interest among advanced cancer patients participating in early phase clinical trials.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(23):3488-94.
2007: Mark J Ratain; Ezra E W Cohen
The value meal: how to save $1,700 per month or more on lapatinib.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(23):3397-8.
2007: Andrea L Yoder Graber; Jacqueline Ramírez; Federico Innocenti; Mark J Ratain
UGT1A1*28 genotype affects the in-vitro glucuronidation of thyroxine in human livers.
Pharmacogenetics and genomics 2007;17(8):619-27.
2007: Antonius A Miller; Daryl J Murry; Kouros Owzar; Donna Hollis; Lionel D Lewis; Hedy L Kindler; John L Marshall; Miguel A Villalona-Calero; Martin J Edelman; Raymond J Hohl; Stuart M Lichtman; Mark J Ratain
Phase I and pharmacokinetic study of erlotinib for solid tumors in patients with hepatic or renal dysfunction: CALGB 60101.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(21):3055-60.
2007: Lionel D Lewis; Antonius A Miller; Gary Rosner; Jonathan E Dowell; Manuel Valdivieso; Mary Relling; Merrill J Egorin; Robert R Bies; Donna Hollis; Ellis G Levine; Gregory A Otterson; Frederick Millard; Mark J Ratain
A comparison of the pharmacokinetics and pharmacodynamics of docetaxel between African-American and Caucasian cancer patients: CALGB 9871.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(11):3302-11.
2007: Laura C Michaelis; Mark J Ratain
Phase II trials published in 2002: a cross-specialty comparison showing significant design differences between oncology trials and other medical specialties.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(8):2400-5.
2007: Mark J Ratain
Personalized medicine: building the GPS to take us there.
Clinical pharmacology and therapeutics 2007;81(3):321-2.
2007: Sandeep D Parsad; Mark J Ratain
Prescribing oral chemotherapy.
BMJ (Clinical research ed.) 2007;334(7590):376.
2007: Gregory A Otterson; Miguel A Villalona-Calero; Sunil Sharma; Mark G Kris; Anthony Imondi; Mirjam Gerber; Dorothy A White; Mark J Ratain; Joan H Schiller; Alan B Sandler; Michael Kraut; Sridhar Mani; John R Murren
Phase I study of inhaled Doxorubicin for patients with metastatic tumors to the lungs.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(4):1246-52.
2007: Fay J Hlubocky; Mark J Ratain; Ming Wen; Christopher K Daugherty
Complementary and alternative medicine among advanced cancer patients enrolled on phase I trials: a study of prognosis, quality of life, and preferences for decision making.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(5):548-54.
2007: Mark J Ratain; Theodore Karrison
Testing the wrong hypothesis in phase II oncology trials: there is a better alternative.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(3):781-2.
2007: Snezana Mirkov; Bernard J Komoroski; Jacqueline Ramírez; Andrea Yoder Graber; Mark J Ratain; Stephen C Strom; Federico Innocenti
Effects of green tea compounds on irinotecan metabolism.
Drug metabolism and disposition: the biological fate of chemicals 2007;35(2):228-33.
2007: Wei Zhang; Wanqing Liu; Federico Innocenti; Mark J Ratain
Searching for tissue-specific expression pattern-linked nucleotides of UGT1A isoforms.
PloS one 2007;2(4):e396.
2007: Roshni P Ramchandani; Yaning Wang; Brian P Booth; Amna Ibrahim; John R Johnson; Atiqur Rahman; Mehul Mehta; Federico Innocenti; Mark J Ratain; Jogarao V S Gobburu
The role of SN-38 exposure, UGT1A1*28 polymorphism, and baseline bilirubin level in predicting severe irinotecan toxicity.
Journal of clinical pharmacology 2007;47(1):78-86.
2006: Federico Innocenti; Mark J Ratain
Pharmacogenetics of irinotecan: clinical perspectives on the utility of genotyping.
Pharmacogenomics 2006;7(8):1211-21.
2006: Dan Mark Roden; Russ B Altman; Neal L Benowitz; David A Flockhart; Kathleen M Giacomini; Julie A Johnson; Ronald M Krauss; howard mcleod; Mark J Ratain; Mary Relling; Huijun Z Ring; Alan R Shuldiner; Richard M Weinshilboum; Scott Weiss
Pharmacogenomics: challenges and opportunities.
Annals of internal medicine 2006;145(10):749-57.
2006: Michael L Maitland; Mark J Ratain
Terminal ballistics of kinase inhibitors: there are no magic bullets.
Annals of internal medicine 2006;145(9):702-3.
2006: Mario Lacouture; Ankit A Desai; Keyoumars Soltani; Vesna Petronic-Rosic; Anne E Laumann; Mark J Ratain; Walter M Stadler
Inflammation of actinic keratoses subsequent to therapy with sorafenib, a multitargeted tyrosine-kinase inhibitor.
Clinical and experimental dermatology 2006;31(6):783-5.
2006: Tim Eisen; T Ahmad; K T Flaherty; Martin Gore; S Kaye; R Marais; I Gibbens; S Hackett; M James; L M Schuchter; Katherine L Nathanson; Chenghua Xia; Ronit Simantov; Brian Schwartz; M Poulin-Costello; P J O'Dwyer; Mark J Ratain
Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis.
British journal of cancer 2006;95(5):581-6.
2006: Michael L Maitland; Kaveeta Vasisht; Mark J Ratain
TPMT, UGT1A1 and DPYD: genotyping to ensure safer cancer therapy?
Trends in pharmacological sciences 2006;27(8):432-7.
2006: Wei Peng Yong; Federico Innocenti; Mark J Ratain
The role of pharmacogenetics in cancer therapeutics.
British journal of clinical pharmacology 2006;62(1):35-46.
2006: Mark J Ratain; Antonius A Miller; howard mcleod; Alan P Venook; Merrill J Egorin; Richard L Schilsky
The cancer and leukemia group B pharmacology and experimental therapeutics committee: a historical perspective.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(11 Pt 2):3612s-6s.
2006: Mark J Ratain; Tim Eisen; Walter M Stadler; Keith T Flaherty; Stan B Kaye; Gary Rosner; Martin Gore; Apurva A Desai; Amita Patnaik; Henry Q Xiong; Eric K Rowinsky; James L Abbruzzese; Chenghua Xia; Ronit Simantov; Brian Schwartz; Peter J O'Dwyer
Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(16):2505-12.
2006: Federico Innocenti; Everett E Vokes; Mark J Ratain
Irinogenetics: what is the right star?
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(15):2221-4.
2006: Michael L Maitland; Anna DiRienzo; Mark J Ratain
Interpreting disparate responses to cancer therapy: the role of human population genetics.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(14):2151-7.
2006: Laura C Michaelis; Mark J Ratain
Measuring response in a post-RECIST world: from black and white to shades of grey.
Nature reviews. Cancer 2006;6(5):409-14.
2006: Stuart M Lichtman; Donna Hollis; Antonius A Miller; Gary Rosner; Chris A Rhoades; Eric P Lester; Frederick Millard; John Byrd; Stephen A Cullinan; D Marc Rosen; Robert A Parise; Mark J Ratain; Merrill J Egorin
Prospective evaluation of the relationship of patient age and paclitaxel clinical pharmacology: Cancer and Leukemia Group B (CALGB 9762).
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(12):1846-51.
2006: Mark J Ratain
From bedside to bench to bedside to clinical practice: an odyssey with irinotecan.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(6):1658-60.
2006: Jacqueline Ramírez; Bernard J Komoroski; Snezana Mirkov; Andrea Yoder Graber; Donna Lee Fackenthal; Erin G Schuetz; Soma Das; Mark J Ratain; Federico Innocenti; Stephen C Strom
Study of the genetic determinants of UGT1A1 inducibility by phenobarbital in cultured human hepatocytes.
Pharmacogenetics and genomics 2006;16(2):79-86.
2006: Cheri E Klein; Helen Kastrissios; Antonius A Miller; Donna Hollis; Daohai Yu; Gary Rosner; David L Grinblatt; Richard A Larson; Mark J Ratain
Pharmacokinetics, pharmacodynamics and adherence to oral topotecan in myelodysplastic syndromes: a Cancer and Leukemia Group B study.
Cancer chemotherapy and pharmacology 2006;57(2):199-206.
2005: Tommy Andersson; David A Flockhart; David B Goldstein; Shiew-Mei Huang; Deanna L Kroetz; Patrice M Milos; Mark J Ratain; Kenneth Thummel
Drug-metabolizing enzymes: evidence for clinical utility of pharmacogenomic tests.
Clinical pharmacology and therapeutics 2005;78(6):559-81.
2005: Walter M Stadler; Laura C Michaelis; Mark J Ratain
Randomized phase II trials and prostate-specific antigen endpoints in prostate cancer: much ado about nothing?
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(31):8124-5; author reply 8125-6.
2005: Apurva A Desai; Hedy L Kindler; David A Taber; Edem Agamah; Sridhar Mani; Kurombi Wade-Oliver; Mark J Ratain; Everett E Vokes
Modulation of irinotecan with cyclosporine: a phase II trial in advanced colorectal cancer.
Cancer chemotherapy and pharmacology 2005;56(4):421-6.
2005: Wei Peng Yong; Jacqueline Ramirez; Federico Innocenti; Mark J Ratain
Effects of ketoconazole on glucuronidation by UDP-glucuronosyltransferase enzymes.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(18):6699-704.
2005: Mark J Ratain
Phase II oncology trials: let's be positive.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(16):5661-2.
2005: Deborah French; Mark R Wilkinson; Wenjian Yang; Luc de Chaisemartin; Edwin H Cook; Soma Das; Mark J Ratain; William Evans; James R Downing; Ching-Hon Pui; Mary Relling
Global gene expression as a function of germline genetic variation.
Human molecular genetics 2005;14(12):1621-9.
2005: Samir D Undevia; Gonzalo Gomez-Abuin; Mark J Ratain
Pharmacokinetic variability of anticancer agents.
Nature reviews. Cancer 2005;5(6):447-58.
2005: Walter M Stadler; Gary Rosner; Eric Small; Donna Hollis; Brian I Rini; S Donald Zaentz; John Mahoney; Mark J Ratain
Successful implementation of the randomized discontinuation trial design: an application to the study of the putative antiangiogenic agent carboxyaminoimidazole in renal cell carcinoma--CALGB 69901.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(16):3726-32.
2005: Apurva A Desai; Richard L Schilsky; A Young; Linda Janisch; Walter M Stadler; Nicholas J Vogelzang; S Cadden; J A Wright; Mark J Ratain
A phase I study of antisense oligonucleotide GTI-2040 given by continuous intravenous infusion in patients with advanced solid tumors.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2005;16(6):958-65.
2005: Federico Innocenti; Wanqing Liu; Peixian Chen; Apurva A Desai; Soma Das; Mark J Ratain
Haplotypes of variants in the UDP-glucuronosyltransferase1A9 and 1A1 genes.
Pharmacogenetics and genomics 2005;15(5):295-301.
2005: Wanqing Liu; Federico Innocenti; Mark J Ratain
Linkage disequilibrium across the UGT1A locus should not be ignored in association studies of cancer susceptibility.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(3):1348-9; author reply 1349.
2005: Apurva A Desai; Mark J Ratain
EGFR pharmacogenomics: the story continues to mutate and evolve.
American journal of pharmacogenomics : genomics-related research in drug development and clinical practice 2005;5(2):137-9.
2005: Wanqing Liu; Federico Innocenti; Michael H Wu; Apurva A Desai; M Eileen Dolan; Edwin H Cook; Mark J Ratain
A functional common polymorphism in a Sp1 recognition site of the epidermal growth factor receptor gene promoter.
Cancer research 2005;65(1):46-53.
2005: John L Marshall; Hedy Kindler; John F Deeken; Pankaj Bhargava; Nicholas J Vogelzang; Naiyer A Rizvi; Taina Luhtala; Stacy Boylan; Margaret Dordal; Philmore Robertson; Michael J Hawkins; Mark J Ratain
Phase I trial of orally administered CEP-701, a novel neurotrophin receptor-linked tyrosine kinase inhibitor.
Investigational new drugs 2005;23(1):31-7.
2004: Antonius A Miller; Gary Rosner; Merrill J Egorin; Donna Hollis; Stuart M Lichtman; Mark J Ratain
Prospective evaluation of body surface area as a determinant of paclitaxel pharmacokinetics and pharmacodynamics in women with solid tumors: Cancer and Leukemia Group B Study 9763.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(24):8325-31.
2004: Todd M Zimmerman; Helena Harlin; Olatoyosi Odenike; Seth Berk; Evie Sprague; Theodore Karrison; Wendy Stock; Richard A Larson; Mark J Ratain; Thomas F Gajewski
Dose-ranging pharmacodynamic study of tipifarnib (R115777) in patients with relapsed and refractory hematologic malignancies.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(23):4816-22.
2004: Olatoyosi Odenike; Ronald Sobecks; Linda Janisch; Dezheng Huo; Todd M Zimmerman; Christopher K Daugherty; Mark J Ratain; Richard A Larson
A phase I trial of gemcitabine plus cladribine in patients with advanced hematologic malignant diseases.
Cancer chemotherapy and pharmacology 2004;54(6):553-61.
2004: Tim A Ahles; James E Herndon; Eric J Small; Nicholas J Vogelzang; Alice B Kornblith; Mark J Ratain; Walter Stadler; David Palchak; M Ernest Marshall; George Wilding; Daniel P Petrylak; Jimmie C Holland
Quality of life impact of three different doses of suramin in patients with metastatic hormone-refractory prostate carcinoma: results of Intergroup O159/Cancer and Leukemia Group B 9480.
Cancer 2004;101(10):2202-8.
2004: Mark J Ratain; S Gail Eckhardt
Phase II studies of modern drugs directed against new targets: if you are fazed, too, then resist RECIST.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(22):4442-5.
2004: Federico Innocenti; Samir D Undevia; Jacqueline Ramírez; Sridhar Mani; Richard L Schilsky; Nicholas J Vogelzang; Marisol Prado; Mark J Ratain
A phase I trial of pharmacologic modulation of irinotecan with cyclosporine and phenobarbital.
Clinical pharmacology and therapeutics 2004;76(5):490-502.
2004: Charles Rudin; John L Marshall; Chao Hui Huang; Hedy L Kindler; Chuanbo Zhang; Deepak Kumar; Prafulla C Gokhale; Joyce Steinberg; Steve Wanaski; Usha N Kasid; Mark J Ratain
Delivery of a liposomal c-raf-1 antisense oligonucleotide by weekly bolus dosing in patients with advanced solid tumors: a phase I study.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(21):7244-51.
2004: Samir D Undevia; Hedy L Kindler; Linda Janisch; S C Olson; Richard L Schilsky; Nicholas J Vogelzang; K A Kimmel; T A Macek; Mark J Ratain
A phase I study of the oral combination of CI-994, a putative histone deacetylase inhibitor, and capecitabine.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2004;15(11):1705-11.
2004: Samir D Undevia; Nicholas J Vogelzang; Ann M Mauer; Linda Janisch; Sridhar Mani; Mark J Ratain
Phase I clinical trial of CEP-2563 dihydrochloride, a receptor tyrosine kinase inhibitor, in patients with refractory solid tumors.
Investigational new drugs 2004;22(4):449-58.
2004: Apurva A Desai; Federico Innocenti; Linda Janisch; Mark DeMario; Dale R Shepard; Jacqueline Ramirez; Gini F Fleming; Mark J Ratain
A phase I trial of pharmacokinetic modulation of carboxyamidotriazole (CAI) with ketoconazole in patients with advanced cancer.
Cancer chemotherapy and pharmacology 2004;54(5):377-84.
2004: Jacqueline Ramírez; Federico Innocenti; Erin G Schuetz; David A Flockhart; Mary Relling; Raymond Santucci; Mark J Ratain
CYP2B6, CYP3A4, and CYP2C19 are responsible for the in vitro N-demethylation of meperidine in human liver microsomes.
Drug metabolism and disposition: the biological fate of chemicals 2004;32(9):930-6.
2004: Christopher W Ryan; Nicholas J Vogelzang; Everett E Vokes; Hedy L Kindler; Samir D Undevia; Rod A Humerickhouse; Amy K André; Qiang Wang; Robert A Carr; Mark J Ratain
Dose-ranging study of the safety and pharmacokinetics of atrasentan in patients with refractory malignancies.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(13):4406-11.
2004: Paul R Helft; Richard L Schilsky; Frank J Hoke; Daphne Williams; Hedy L Kindler; Evie Sprague; Mark DeWitte; Helen K Martino; John Erickson; Lini Pandite; Mark Russo; John M Lambert; Maria Howard; Mark J Ratain
A phase I study of cantuzumab mertansine administered as a single intravenous infusion once weekly in patients with advanced solid tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(13):4363-8.
2004: M Eileen Dolan; Karla G Newbold; Ramamoorthy Nagasubramanian; Xiaolin Wu; Mark J Ratain; Edwin H Cook; Judith A Badner
Heritability and linkage analysis of sensitivity to cisplatin-induced cytotoxicity.
Cancer research 2004;64(12):4353-6.
2004: Federico Innocenti; Mark J Ratain
"Irinogenetics" and UGT1A: from genotypes to haplotypes.
Clinical pharmacology and therapeutics 2004;75(6):495-500.
2004: Paul R Helft; Mark J Ratain; Richard A Epstein; Mark Siegler
Inside information: Financial conflicts of interest for research subjects in early phase clinical trials.
Journal of the National Cancer Institute 2004;96(9):656-61.
2004: Jeffrey A Meyerhardt; Ambrose Kwok; Mark J Ratain; J Patrick McGovren; Charlie S Fuchs
Relationship of baseline serum bilirubin to efficacy and toxicity of single-agent irinotecan in patients with metastatic colorectal cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(8):1439-46.
2004: Federico Innocenti; Samir D Undevia; Lalitha Iyer; Pei Xian Chen; Soma Das; Masha Kocherginsky; Theodore Karrison; Linda Janisch; Jacqueline Ramírez; Charles Rudin; Everett E Vokes; Mark J Ratain
Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(8):1382-8.
2004: Gretchen Kimmick; Mark J Ratain; Don Berry; Susan Woolf; Larry Norton; Hyman Muss
Subcutaneously administered recombinant human interleukin-2 and interferon alfa-2a for advanced breast cancer: a phase II study of the Cancer and Leukemia Group B (CALGB 9041).
Investigational new drugs 2004;22(1):83-9.
2004: Nicholas J Vogelzang; Theodore Karrison; Walter M Stadler; Juan Garcia; Helene Cohn; John Kugler; Thomas Troeger; Leonard Giannone; Rose Arrieta; Mark J Ratain; Everett E Vokes
A Phase II trial of suramin monthly x 3 for hormone-refractory prostate carcinoma.
Cancer 2004;100(1):65-71.
2003: A P Venook; C Enders Klein; G Fleming; D Hollis; C G Leichman; R Hohl; John Byrd; D Budman; M Villalona; J Marshall; Gary Rosner; J Ramirez; Helen Kastrissios; Mark J Ratain
A phase I and pharmacokinetic study of irinotecan in patients with hepatic or renal dysfunction or with prior pelvic radiation: CALGB 9863.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2003;14(12):1783-90.
2003: Apurva A Desai; Federico Innocenti; Mark J Ratain
Pharmacogenomics: road to anticancer therapeutics nirvana?
Oncogene 2003;22(42):6621-8.
2003: Mark J Ratain
Finding the right dose.
Clinical advances in hematology & oncology : H&O 2003;1(9):517-8, 531.
2003: Apurva A Desai; Federico Innocenti; Mark J Ratain
UGT pharmacogenomics: implications for cancer risk and cancer therapeutics.
Pharmacogenetics 2003;13(8):517-23.
2003: Patrick T Murray; Mark J Ratain
Estimation of the glomerular filtration rate in cancer patients: a new formula for new drugs.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(14):2633-5.
2003: Gini F Fleming; Richard L Schilsky; L Philip Schumm; A Meyerson; A M Hong; Nicholas J Vogelzang; Mark J Ratain
Phase I and pharmacokinetic study of 24-hour infusion 5-fluorouracil and leucovorin in patients with organ dysfunction.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2003;14(7):1142-7.
2003: Michael B Sawyer; Federico Innocenti; Soma Das; Cheng Cheng; Jacqueline Ramírez; Friedl H Pantle-Fisher; Constance Wright; Judith A Badner; Deqing Pei; James M Boyett; Edwin H Cook; Mark J Ratain
A pharmacogenetic study of uridine diphosphate-glucuronosyltransferase 2B7 in patients receiving morphine.
Clinical pharmacology and therapeutics 2003;73(6):566-74.
2003: Wallace Akerley; James E Herndon; Merrill J Egorin; Alan P Lyss; Hedy L Kindler; Dianne M Savarese; Carol A Sherman; D Marc Rosen; Donna Hollis; Mark J Ratain; Mark R Green
Weekly, high-dose paclitaxel in advanced lung carcinoma: a phase II study with pharmacokinetics by the Cancer and Leukemia Group B.
Cancer 2003;97(10):2480-6.
2003: Federico Innocenti; Mark J Ratain
Irinotecan treatment in cancer patients with UGT1A1 polymorphisms.
Oncology (Williston Park, N.Y.) 2003;17(5 Suppl 5):52-5.
2003: Michael B Sawyer; Mark J Ratain; Donna Bertucci; Robert P Smith; Richard L Schilsky; Nicholas J Vogelzang; Keith Shulman; Edwin C Douglass; Gini F Fleming
Phase I study of an oral formulation of ZD9331 administered daily for 28 days.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(9):1859-65.
2003: Wanqing Liu; Federico Innocenti; Peixian Chen; Soma Das; Edwin H Cook; Mark J Ratain
Interethnic difference in the allelic distribution of human epidermal growth factor receptor intron 1 polymorphism.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(3):1009-12.
2003: Gregory A Masters; Bruce E Brockstein; Sridhar Mani; Mark J Ratain
Phase 1 dose escalation study of docetaxel with filgrastim support in patients with advanced solid tumors.
Medical oncology (Northwood, London, England) 2003;20(1):7-12.
2003: Ramamoorthy Nagasubramanian; Federico Innocenti; Mark J Ratain
Pharmacogenetics in cancer treatment.
Annual review of medicine 2003;54():437-52.
2002: Cheri E Klein; Elora Gupta; Joel M Reid; Pamela J Atherton; Jeff A Sloan; Henry C Pitot; Mark J Ratain; Helen Kastrissios
Population pharmacokinetic model for irinotecan and two of its metabolites, SN-38 and SN-38 glucuronide.
Clinical pharmacology and therapeutics 2002;72(6):638-47.
2002: Gini F Fleming; Neal J Meropol; Gary Rosner; Donna Hollis; William E Carson; Michael Caligiuri; Joanne Mortimer; Katherine Tkaczuk; Robin Parihar; Richard L Schilsky; Mark J Ratain
A phase I trial of escalating doses of trastuzumab combined with daily subcutaneous interleukin 2: report of cancer and leukemia group B 9661.
Clinical cancer research : an official journal of the American Association for Cancer Research 2002;8(12):3718-27.
2002: Federico Innocenti; Carrie Grimsley; Soma Das; Jacqueline Ramírez; Cheng Cheng; Hala Kuttab-Boulos; Mark J Ratain; Anna Di Rienzo
Haplotype structure of the UDP-glucuronosyltransferase 1A1 promoter in different ethnic groups.
Pharmacogenetics 2002;12(9):725-33.
2002: Gary Rosner; Walter Stadler; Mark J Ratain
Randomized discontinuation design: application to cytostatic antineoplastic agents.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(22):4478-84.
2002: Jan H M Schellens; Mark J Ratain
Endostatin: are the 2 years up yet?
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(18):3758-60.
2002: Eric J Small; Susan Halabi; Mark J Ratain; Gary Rosner; Walter Stadler; David Palchak; Ernest Marshall; Randall Rago; Vera Hars; George Wilding; Daniel P Petrylak; Nicholas J Vogelzang
Randomized study of three different doses of suramin administered with a fixed dosing schedule in patients with advanced prostate cancer: results of intergroup 0159, cancer and leukemia group B 9480.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(16):3369-75.
2002: Chetan Lathia; Gini F Fleming; Mark Meyer; Mark J Ratain; Lloyd Whitfield
Pentostatin pharmacokinetics and dosing recommendations in patients with mild renal impairment.
Cancer chemotherapy and pharmacology 2002;50(2):121-6.
2002: M Eileen Dolan; Mitchell Posner; Theodore Karrison; Jonathan M Radosta; Gary Steinberg; Donna Bertucci; Lucky Vujasin; Mark J Ratain
Determination of the optimal modulatory dose of O6-benzylguanine in patients with surgically resectable tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research 2002;8(8):2519-23.
2002: Christopher W Ryan; Everett E Vokes; Nicholas J Vogelzang; Linda Janisch; Ken Kobayashi; Mark J Ratain
A phase I study of suramin with once- or twice-monthly dosing in patients with advanced cancer.
Cancer chemotherapy and pharmacology 2002;50(1):1-5.
2002: Jacqueline Ramírez; Lalitha Iyer; Kim Journault; Patrick Bélanger; Federico Innocenti; Mark J Ratain; Chantal Guillemette
In vitro characterization of hepatic flavopiridol metabolism using human liver microsomes and recombinant UGT enzymes.
Pharmaceutical research 2002;19(5):588-94.
2002: Federico Innocenti; Mark J Ratain
Correspondence re: Raida, M. et al., prevalence of a common point mutation in the dihydropyrimidine dehydrogenase (DPD) gene within the 5'-splice donor site of intron 14 in patients with severe 5-fluorouracil (5-FU)-related toxicity compared with controls.
Clinical cancer research : an official journal of the American Association for Cancer Research 2002;8(5):1314; author reply 1315-6.
2002: Dale R Shepard; Sridhar Mani; Helen Kastrissios; Susan Learned-Coughlin; Deborah Smith; Phillip Ertel; Steve Magnum; Linda Janisch; Gini F Fleming; Richard L Schilsky; Mark J Ratain
Estimation of the effect of food on the disposition of oral 5-fluorouracil in combination with eniluracil.
Cancer chemotherapy and pharmacology 2002;49(5):398-402.
2002: Sridhar Mani; Charles Rudin; Katie Kunkel; Jon T Holmlund; Richard S Geary; Hedy L Kindler; F Andrew Dorr; Mark J Ratain
Phase I clinical and pharmacokinetic study of protein kinase C-alpha antisense oligonucleotide ISIS 3521 administered in combination with 5-fluorouracil and leucovorin in patients with advanced cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2002;8(4):1042-8.
2002: Lalitha Iyer; Jacqueline Ramírez; Dale R Shepard; Christopher M Bingham; Dieter K Hossfeld; Mark J Ratain; Ulrich Mayer
Biliary transport of irinotecan and metabolites in normal and P-glycoprotein-deficient mice.
Cancer chemotherapy and pharmacology 2002;49(4):336-41.
2002: Mark J Ratain
Dear doctor: we really are not sure what dose of capecitabine you should prescribe for your patient.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(6):1434-5.
2002: Federico Innocenti; Mark J Ratain
Update on pharmacogenetics in cancer chemotherapy.
European journal of cancer (Oxford, England : 1990) 2002;38(5):639-44.
2002: B C Goh; Everett E Vokes; A Joshi; Mark J Ratain
Phase I study of the combination of losoxantrone and cyclophosphamide in patients with refractory solid tumours.
British journal of cancer 2002;86(4):534-9.
2002: Richard L Schilsky; Donna Bertucci; Nicholas J Vogelzang; Hedy L Kindler; Mark J Ratain
Dose-escalating study of capecitabine plus gemcitabine combination therapy in patients with advanced cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(2):582-7.
2002: Lalitha Iyer; Soma Das; Linda Janisch; M Wen; Jacqueline Ramírez; Theodore Karrison; Gini F Fleming; Everett E Vokes; Richard L Schilsky; Mark J Ratain
UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity.
The pharmacogenomics journal 2002;2(1):43-7.
2002: Mark J Ratain
Irinotecan dosing: does the CPT in CPT-11 stand for "Can't Predict Toxicity"?
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(1):7-8.
2001: Cathy Eng; Ann M Mauer; Gini F Fleming; Donna Bertucci; Jacob Rotmensch; R H Jacobs; Mark J Ratain
Phase I study of pegylated liposomal doxorubicin, paclitaxel, and cisplatin in patients with advanced solid tumors.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2001;12(12):1743-7.
2001: Sridhar Mani; Nicholas J Vogelzang; Donna Bertucci; Walter M Stadler; Richard L Schilsky; Mark J Ratain
Phase I study to evaluate multiple regimens of intravenous 5-fluorouracil administered in combination with weekly gemcitabine in patients with advanced solid tumors: a potential broadly active regimen for advanced solid tumor malignancies.
Cancer 2001;92(6):1567-76.
2001: M Sawyer; Mark J Ratain
Body surface area as a determinant of pharmacokinetics and drug dosing.
Investigational new drugs 2001;19(2):171-7.
2001: Charles Rudin; Jon T Holmlund; Gini F Fleming; Sridhar Mani; Walter M Stadler; Phil L Schumm; Brett P Monia; JF Johnston; Richard S Geary; Zhengrong Yu; T Jesse Kwoh; F Andrew Dorr; Mark J Ratain
Phase I Trial of ISIS 5132, an antisense oligonucleotide inhibitor of c-raf-1, administered by 24-hour weekly infusion to patients with advanced cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2001;7(5):1214-20.
2001: Federico Innocenti; Lalitha Iyer; Jacqueline Ramírez; MD Green; Mark J Ratain
Epirubicin glucuronidation is catalyzed by human UDP-glucuronosyltransferase 2B7.
Drug metabolism and disposition: the biological fate of chemicals 2001;29(5):686-92.
2001: Reginald Ewesuedo; Lalitha Iyer; Soma Das; A Koenig; Sridhar Mani; Nicholas J Vogelzang; Richard L Schilsky; W Brenckman; Mark J Ratain
Phase I clinical and pharmacogenetic study of weekly TAS-103 in patients with advanced cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2001;19(7):2084-90.
2001: Federico Innocenti; Lalitha Iyer; Mark J Ratain
Pharmacogenetics of anticancer agents: lessons from amonafide and irinotecan.
Drug metabolism and disposition: the biological fate of chemicals 2001;29(4 Pt 2):596-600.
2001: B C Goh; Mark J Ratain; Donna Bertucci; R Smith; Sridhar Mani; Nicholas J Vogelzang; Richard L Schilsky; M Hutchison; M Smith; Steven Averbuch; E Douglass
Phase I study of ZD9331 on short daily intravenous bolus infusion for 5 days every 3 weeks with fixed dosing recommendations.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2001;19(5):1476-84.
2001: Helen Kastrissios; Mark J Ratain
Screening for sources of interindividual pharmacokinetic variability in anticancer drug therapy: utility of population analysis.
Cancer investigation 2001;19(1):57-64.
2000: Federico Innocenti; Lalitha Iyer; Mark J Ratain
Pharmacogenetics: a tool for individualizing antineoplastic therapy.
Clinical pharmacokinetics 2000;39(5):315-25.
2000: Federico Innocenti; Walter M Stadler; L Iyer; Jacqueline Ramírez; Everett E Vokes; Mark J Ratain
Flavopiridol metabolism in cancer patients is associated with the occurrence of diarrhea.
Clinical cancer research : an official journal of the American Association for Cancer Research 2000;6(9):3400-5.
2000: Richard L Schilsky; M Eileen Dolan; Donna Bertucci; Reginald Ewesuedo; Nicholas J Vogelzang; Sridhar Mani; Lynette R Wilson; Mark J Ratain
Phase I clinical and pharmacological study of O6-benzylguanine followed by carmustine in patients with advanced cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2000;6(8):3025-31.
2000: Alan P Venook; Merrill J Egorin; Gary Rosner; Donna Hollis; Sridhar Mani; M Hawkins; John Byrd; R Hohl; D Budman; N J Meropol; Mark J Ratain
Phase I and pharmacokinetic trial of gemcitabine in patients with hepatic or renal dysfunction: Cancer and Leukemia Group B 9565.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2000;18(14):2780-7.
2000: Christopher W Ryan; Gini F Fleming; Linda Janisch; Mark J Ratain
A phase I study of liposomal doxorubicin (Doxil) with topotecan.
American journal of clinical oncology 2000;23(3):297-300.
2000: Christopher K Daugherty; Donald M Banik; L Janish; Mark J Ratain
Quantitative analysis of ethical issues in phase I trials: a survey interview of 144 advanced cancer patients.
IRB 2000;22(3):6-14.
2000: Walter M Stadler; Mark J Ratain
Development of target-based antineoplastic agents.
Investigational new drugs 2000;18(1):7-16.
2000: B C Goh; Gini F Fleming; Linda Janisch; Nicholas J Vogelzang; Walter M Stadler; Mark J Ratain
Development of a schedule-dependent population pharmacodynamic model for rhizoxin without quantitation of plasma concentrations.
Cancer chemotherapy and pharmacology 2000;45(6):489-94.
1999: Everett E Vokes; B C Goh; Donna Bertucci; Nicholas J Vogelzang; Sridhar Mani; Mark J Ratain
A Phase I study of raltitrexed and paclitaxel given every 3 weeks to patients with solid tumors.
Cancer 1999;86(3):528-32.
1999: H Minami; T E Lad; M Kelly Nicholas; Everett E Vokes; Mark J Ratain
Pharmacokinetics and pharmacodynamics of 9-aminocamptothecin infused over 72 hours in phase II studies.
Clinical cancer research : an official journal of the American Association for Cancer Research 1999;5(6):1325-30.
1999: Lalitha Iyer; D Hall; Soma Das; M A Mortell; Jacqueline Ramírez; S Kim; Anna Di Rienzo; Mark J Ratain
Phenotype-genotype correlation of in vitro SN-38 (active metabolite of irinotecan) and bilirubin glucuronidation in human liver tissue with UGT1A1 promoter polymorphism.
Clinical pharmacology and therapeutics 1999;65(5):576-82.
1999: Rod A Humerickhouse; M Eileen Dolan; Daniel J Haraf; Bruce E Brockstein; Kerstin M Stenson; Merrill S Kies; L Sulzen; Mark J Ratain; Everett E Vokes
Phase I study of eniluracil, a dihydropyrimidine dehydrogenase inactivator, and oral 5-fluorouracil with radiation therapy in patients with recurrent or advanced head and neck cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 1999;5(2):291-8.
1999: Lalitha Iyer; Mark J Ratain
5-fluorouracil pharmacokinetics: causes for variability and strategies for modulation in cancer chemotherapy.
Cancer investigation 1999;17(7):494-506.
1999: Mark DeMario; Mark J Ratain; Nicholas J Vogelzang; Sridhar Mani; Everett E Vokes; Gini F Fleming; K Melton; S Johnson; S Benner; D Lebwohl
A phase I study of oral uracil/ftorafur (UFT) plus leucovorin and bis-acetato-ammine-dichloro-cyclohexylamine-platinum IV (JM-216) each given over 14 days every 28 days.
Cancer chemotherapy and pharmacology 1999;43(5):385-8.
1998: L K House; J Ramírez; Mark J Ratain
Simultaneous determination of 5-fluorouracil and uracil by high-performance liquid chromatography using four serial columns.
Journal of chromatography. B, Biomedical sciences and applications 1998;720(1-2):245-50.
1998: Everett E Vokes; Rafat H Ansari; Gregory A Masters; Philip C Hoffman; A Klepsch; Mark J Ratain; David F Sciortino; T E Lad; Stuart Krauss; Paul A. Fishkin; HM Golomb
A phase II study of 9-aminocamptothecin in advanced non-small-cell lung cancer.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1998;9(10):1085-90.
1998: Lalitha Iyer; Mark J Ratain
Pharmacogenetics and cancer chemotherapy.
European journal of cancer (Oxford, England : 1990) 1998;34(10):1493-9.
1998: Mark DeMario; Mark J Ratain
Oral chemotherapy: rationale and future directions.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1998;16(7):2557-67.
1998: Christopher K Daugherty; Mark J Ratain; H Minami; Donald M Banik; Nicholas J Vogelzang; Walter M Stadler; Mark Siegler
Study of cohort-specific consent and patient control in phase I cancer trials.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1998;16(7):2305-12.
1998: Gini F Fleming; John W Kugler; Philip C Hoffman; Rafat H Ansari; Jacob Bitran; A Klepsch; D Malone; AA Fasanmade; Mark J Ratain; Everett E Vokes
Phase II trial of paclitaxel and topotecan with granulocyte colony-stimulating factor support in stage IV breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1998;16(6):2032-7.
1998: M Eileen Dolan; S K Roy; AA Fasanmade; P R Paras; Richard L Schilsky; Mark J Ratain
O6-benzylguanine in humans: metabolic, pharmacokinetic, and pharmacodynamic findings.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1998;16(5):1803-10.
1998: Nicholas J Vogelzang; Sridhar Mani; Richard L Schilsky; Rafat H Ansari; David A Taber; S N Rhinehart; JC Garcia; S C Meyer; R Mick; Bruce E Brockstein; Walter M Stadler; Mark J Ratain; Everett E Vokes
Phase II and pharmacodynamic studies of pyrazine diazohydroxide (NSC 361456) in patients with advanced renal and colorectal cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 1998;4(4):929-34.
1998: Richard L Schilsky; JA Hohneker; Mark J Ratain; Linda Janisch; Leslie Ann Smetzer; V S Lucas; SP Khor; R Diasio; Daniel Von Hoff; Howard A Burris
Phase I clinical and pharmacologic study of eniluracil plus fluorouracil in patients with advanced cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1998;16(4):1450-7.
1998: Brian I Rini; Walter M Stadler; R T Spielberger; Mark J Ratain; Nicholas J Vogelzang
Granulocyte-macrophage--colony stimulating factor in metastatic renal cell carcinoma: a phase II trial.
Cancer 1998;82(7):1352-8.
1998: Lalitha Iyer; Christopher D King; P F Whitington; MD Green; S K Roy; Thomas R Tephly; Birgit L Coffman; Mark J Ratain
Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes.
The Journal of clinical investigation 1998;101(4):847-54.
1998: Bruce E Brockstein; Daniel J Haraf; Kerstin M Stenson; AA Fasanmade; R Stupp; B Glisson; S M Lippman; Mark J Ratain; L Sulzen; A Klepsch; Ralph R Weichselbaum; Everett E Vokes
Phase I study of concomitant chemoradiotherapy with paclitaxel, fluorouracil, and hydroxyurea with granulocyte colony-stimulating factor support for patients with poor-prognosis cancer of the head and neck.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1998;16(2):735-44.
1998: Lalitha Iyer; Mark J Ratain
Clinical pharmacology of camptothecins.
Cancer chemotherapy and pharmacology 1998;42 Suppl():S31-43.
1998: Sridhar Mani; Lalitha Iyer; Linda Janisch; X Wang; Gini F Fleming; Richard L Schilsky; Mark J Ratain
Phase I clinical and pharmacokinetic study of oral 9-aminocamptothecin (NSC-603071).
Cancer chemotherapy and pharmacology 1998;42(1):84-7.
1997: Mark DeMario; Mark J Ratain
Rationale for phase I study of UFT plus leucovorin and oral JM-216.
Oncology (Williston Park, N.Y.) 1997;11(9 Suppl 10):26-9.
1997: Mark J Ratain; L A Skoog; S M O'Brien; N Cooper; Richard L Schilsky; Nicholas J Vogelzang; M Gerber; P K Narang; S J Nicol
Phase I study of 3'-deamino-3'-(2-methoxy-4-morpholinyl)doxorubicin (FCE 23762, PNU 152243) administered on a daily x3 schedule.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1997;8(8):807-9.
1997: Christopher K Daugherty; Mark Siegler; Mark J Ratain; G Zimmer
Learning from our patients: one participant's impact on clinical trial research and informed consent.
Annals of internal medicine 1997;126(11):892-7.
1997: E Gupta; R Mick; J Ramirez; X Wang; T M Lestingi; Everett E Vokes; Mark J Ratain
Pharmacokinetic and pharmacodynamic evaluation of the topoisomerase inhibitor irinotecan in cancer patients.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1997;15(4):1502-10.
1997: Sridhar Mani; Mark J Ratain
New phase I trial methodology.
Seminars in oncology 1997;24(2):253-61.
1997: E Gupta; X Wang; Jacqueline Ramirez; Mark J Ratain
Modulation of glucuronidation of SN-38, the active metabolite of irinotecan, by valproic acid and phenobarbital.
Cancer chemotherapy and pharmacology 1997;39(5):440-4.
1997: Jacqueline Ramírez; K Ogan; Mark J Ratain
Determination of vinca alkaloids in human plasma by liquid chromatography/atmospheric pressure chemical ionization mass spectrometry.
Cancer chemotherapy and pharmacology 1997;39(4):286-90.
1997: Gini F Fleming; S M O'Brien; Philip C Hoffman; Everett E Vokes; Nicholas J Vogelzang; Richard L Schilsky; S E Waggoner; Mark J Ratain
Phase I study of treatment with oral 13-cis-retinoic acid, subcutaneous interferon alfa-2a, cisplatin, and 24-hour infusion 5-fluorouracil/leucovorin.
Cancer chemotherapy and pharmacology 1997;39(3):227-32.
1997: Betty Soliven; U K Dhand; Ken Kobayashi; R Arora; B Martin; M V Petersen; Linda Janisch; Nicholas J Vogelzang; Everett E Vokes; Mark J Ratain
Evaluation of neuropathy in patients on suramin treatment.
Muscle & nerve 1997;20(1):83-91.
1996: K Kobayashi; R E Weiss; Nicholas J Vogelzang; Everett E Vokes; Linda Janisch; Mark J Ratain
Mineralocorticoid insufficiency due to suramin therapy.
Cancer 1996;78(11):2411-20.
1996: Sridhar Mani; Mark J Ratain
Promising new agents in oncologic treatment.
Current opinion in oncology 1996;8(6):525-34.
1996: K Kobayashi; Everett E Vokes; Nicholas J Vogelzang; Linda Janisch; Betty Soliven; Mark J Ratain
Phase I study of suramin administered by intermittent infusion without adaptive control to cancer patients: update of two expanded dose levels near the maximally tolerated dose.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1996;14(9):2622-3.
1996: R Mick; E Gupta; Everett E Vokes; Mark J Ratain
Limited-sampling models for irinotecan pharmacokinetics-pharmacodynamics: prediction of biliary index and intestinal toxicity.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1996;14(7):2012-9.
1996: Gini F Fleming; Linda Janisch; Nicholas J Vogelzang; Everett E Vokes; Mark J Ratain
Phase I study of escalating doses of mitoxantrone and paclitaxel with granulocyte-macrophage colony stimulating factor support.
Cancer 1996;77(11):2308-12.
1996: Everett E Vokes; R Mick; Merrill S Kies; M Eileen Dolan; D Malone; I Athanasiadis; Daniel J Haraf; Mark F. Kozloff; Ralph R Weichselbaum; Mark J Ratain
Pharmacodynamics of fluorouracil-based induction chemotherapy in advanced head and neck cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1996;14(5):1663-71.
1996: E Gupta; Ahmad R Safa; X Wang; Mark J Ratain
Pharmacokinetic modulation of irinotecan and metabolites by cyclosporin A.
Cancer research 1996;56(6):1309-14.
1996: R Mick; Everett E Vokes; T M Lestingi; W Gray-Stern; Gini F Fleming; Richard L Schilsky; Mark J Ratain
Etoposide combined with interferon alfa-2b: novel exploitation of established etoposide pharmacokinetics and pharmacodynamics.
Clinical pharmacology and therapeutics 1996;59(3):349-59.
1996: Mark J Ratain; R Mick; Linda Janisch; F Berezin; Richard L Schilsky; Nicholas J Vogelzang; M Kut
Individualized dosing of amonafide based on a pharmacodynamic model incorporating acetylator phenotype and gender.
Pharmacogenetics 1996;6(1):93-101.
1996: H Minami; J H Beijnen; J Verweij; Mark J Ratain
Limited sampling model for area under the concentration time curve of total topotecan.
Clinical cancer research : an official journal of the American Association for Cancer Research 1996;2(1):43-6.
1996: H Minami; Mark J Ratain; Y Ando; K Shimokata
Pharmacodynamic modeling of prolonged administration of etoposide.
Cancer chemotherapy and pharmacology 1996;39(1-2):61-6.
1996: Richard A Larson; R Mick; R T Spielberger; S M O'Brien; Mark J Ratain
Dose-escalation trial of cladribine using five daily intravenous infusions in patients with advanced hematologic malignancies.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1996;14(1):188-95.
1995: E Gupta; Olufunmilayo I Olopade; Mark J Ratain; R Mick; T M Baker; F K Berezin; A B Benson; M Eileen Dolan
Pharmacokinetics and pharmacodynamics of oltipraz as a chemopreventive agent.
Clinical cancer research : an official journal of the American Association for Cancer Research 1995;1(10):1133-8.
1995: K Kobayashi; Everett E Vokes; Nicholas J Vogelzang; L Janish; Betty Soliven; Mark J Ratain
Phase I study of suramin given by intermittent infusion without adaptive control in patients with advanced cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1995;13(9):2196-207.
1995: Christopher K Daugherty; Mark J Ratain; E Grochowski; C Stocking; E Kodish; R Mick; Mark Siegler
Perceptions of cancer patients and their physicians involved in phase I trials.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1995;13(5):1062-72.
1995: Mark J Ratain; Gary Rosner; S L Allen; M Costanza; David A Van Echo; I C Henderson; Richard L Schilsky
Population pharmacodynamic study of amonafide: a Cancer and Leukemia Group B study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1995;13(3):741-7.
1995: Richard A Larson; RB Geller; Linda Janisch; J Milton; Louise B. Grochow; Mark J Ratain
Encephalopathy is the dose-limiting toxicity of intravenous hepsulfam: results of a phase I trial in patients with advanced hematological malignancies.
Cancer chemotherapy and pharmacology 1995;36(3):204-10.
1994: R Mick; N Lane; Christopher K Daugherty; Mark J Ratain
Physician-determined patient risk of toxic effects: impact on enrollment and decision making in phase I cancer trials.
Journal of the National Cancer Institute 1994;86(22):1685-93.
1994: Linda Janisch; R Mick; Richard L Schilsky; Nicholas J Vogelzang; S O'Brien; M Kut; Mark J Ratain
Prognostic factors for survival in patients treated in phase I clinical trials.
Cancer 1994;74(7):1965-73.
1994: R Mick; Mark J Ratain
Bootstrap validation of pharmacodynamic models defined via stepwise linear regression.
Clinical pharmacology and therapeutics 1994;56(2):217-22.
1994: E Gupta; T M Lestingi; R Mick; J Ramirez; Everett E Vokes; Mark J Ratain
Metabolic fate of irinotecan in humans: correlation of glucuronidation with diarrhea.
Cancer research 1994;54(14):3723-5.
1994: L C Platanias; Mark J Ratain; S O'Brien; Richard A Larson; James W Vardiman; J P Shaw; Stephanie F Williams; Joseph M Baron; K Parker; T G Woodworth
Phase I trial of a genetically engineered interleukin-2 fusion toxin (DAB486IL-2) as a 6 hour intravenous infusion in patients with hematologic malignancies.
Leukemia & lymphoma 1994;14(3-4):257-62.
1994: K Kobayashi; Nicholas J Vogelzang; S M O'Brien; Richard L Schilsky; Everett E Vokes; Mark J Ratain
A phase I study of intermittent infusion cladribine in patients with solid tumors.
Cancer 1994;74(1):168-73.
1994: Gini F Fleming; Mark J Ratain; S M O'Brien; Richard L Schilsky; Philip C Hoffman; J M Richards; Nicholas J Vogelzang; D A Kasunic; R H Earhart
Phase I study of adozelesin administered by 24-hour continuous intravenous infusion.
Journal of the National Cancer Institute 1994;86(5):368-72.
1994: Nicholas J Vogelzang; R Mick; Linda Janisch; F Berezin; Richard L Schilsky; Mark J Ratain
Phase I and pharmacokinetic study of a new antineoplastic agent: pyrazine diazohydroxide (NSC 361456).
Cancer research 1994;54(1):114-9.
1994: K Kobayashi; Mark J Ratain
Pharmacodynamics and long-term toxicity of etoposide.
Cancer chemotherapy and pharmacology 1994;34 Suppl():S64-8.
1994: R B Mitchell; M Eileen Dolan; Linda Janisch; Nicholas J Vogelzang; Mark J Ratain; Richard L Schilsky
Sequential therapy with dacarbazine and carmustine: a phase I study.
Cancer chemotherapy and pharmacology 1994;34(6):509-14.
1994: R T Spielberger; R Mick; Mark J Ratain; HM Golomb
Interferon treatment for hairy cell leukemia. An update on a cohort of 69 patients treated from 1983 to 1986.
Leukemia & lymphoma 1994;14 Suppl 1():89-93.
1993: Mark J Ratain; R Mick; Richard L Schilsky; Mark Siegler
Statistical and ethical issues in the design and conduct of phase I and II clinical trials of new anticancer agents.
Journal of the National Cancer Institute 1993;85(20):1637-43.
1993: Brian L Samuels; R Mick; Nicholas J Vogelzang; Stephanie F Williams; Richard L Schilsky; Ahmad R Safa; S M O'Brien; Mark J Ratain
Modulation of vinblastine resistance with cyclosporine: a phase I study.
Clinical pharmacology and therapeutics 1993;54(4):421-9.
1993: Everett E Vokes; M E Dolan; S Krishnasamy; R Mick; Mark J Ratain; F Berezin; D Brachman; G Whitman; Richard L Schilsky; J Charette
5-Fluorouracil, hydroxyurea and escalating doses of iododeoxyuridine with concomitant radiotherapy for malignant gliomas: a clinical and pharmacologic analysis.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1993;4(7):591-5.
1993: Mark J Ratain; R Mick; F Berezin; Linda Janisch; Richard L Schilsky; Nicholas J Vogelzang; L B Lane
Phase I study of amonafide dosing based on acetylator phenotype.
Cancer research 1993;53(10 Suppl):2304-8.
1993: Mark J Ratain; E R Priest; Linda Janisch; Nicholas J Vogelzang
A phase I study of subcutaneous recombinant interleukin-2 and interferon alfa-2a.
Cancer 1993;71(7):2371-6.
1993: Richard L Schilsky; Linda Janisch; F Berezin; R Mick; Nicholas J Vogelzang; Mark J Ratain
Phase I clinical and pharmacological study of iododeoxyuridine and bleomycin in patients with advanced cancer.
Cancer research 1993;53(6):1293-6.
1993: R Mick; Mark J Ratain
Model-guided determination of maximum tolerated dose in phase I clinical trials: evidence for increased precision.
Journal of the National Cancer Institute 1993;85(3):217-23.
1993: K Kobayashi; Mark J Ratain
Individualizing dosing of cancer chemotherapy.
Seminars in oncology 1993;20(1):30-42.
1993: Everett E Vokes; Mark J Ratain; R Mick; J M McEvilly; Daniel J Haraf; Mark F. Kozloff; V Hamasaki; Ralph R Weichselbaum; WR Panje; Barry L Wenig
Cisplatin, fluorouracil, and leucovorin augmented by interferon alfa-2b in head and neck cancer: a clinical and pharmacologic analysis.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1993;11(2):360-8.
1993: Richard L Schilsky; Mark J Ratain; Linda Janisch; Nicholas J Vogelzang; V S Lucas; J Ravitch; JA Hohneker; N J Clendeninn; R L Tuttle
Phase I clinical and pharmacology study of 502U83 given as a 24-h continuous intravenous infusion.
Cancer chemotherapy and pharmacology 1993;31(4):283-8.
1993: Everett E Vokes; S M O'Brien; Nicholas J Vogelzang; Richard L Schilsky; Mark J Ratain
Five-day infusional fluorodeoxyuridine with oral leucovorin and escalating doses of interferon alpha-2b: a phase I study.
Cancer chemotherapy and pharmacology 1993;32(5):347-52.
1993: R Mick; Mark J Ratain
Statistical approaches to pharmacodynamic modeling: motivations, methods, and misperceptions.
Cancer chemotherapy and pharmacology 1993;33(1):1-9.
1992: K Kobayashi; Mark J Ratain
New perspectives on the toxicity of etoposide.
Seminars in oncology 1992;19(6 Suppl 13):78-83.
1992: K Kobayashi; Everett E Vokes; K Stefansson; Linda Janisch; Nicholas J Vogelzang; F Berezin; Mark J Ratain
Suramin: is adaptive control necessary?
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1992;10(12):1984-5; author reply 1985-6.
1992: HM Golomb; Mark J Ratain; R Mick; K Daly
Interferon treatment for hairy cell leukemia: an update on a cohort of 69 patients treated from 1983-1986.
Leukemia 1992;6(11):1177-80.
1992: E Kodish; C Stocking; Mark J Ratain; A Kohrman; Mark Siegler
Ethical issues in phase I oncology research: a comparison of investigators and institutional review board chairpersons.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1992;10(11):1810-6.
1992: Mark J Ratain
Therapeutic relevance of pharmacokinetics and pharmacodynamics.
Seminars in oncology 1992;19(4 Suppl 11):8-13.
1992: Richard L Schilsky; Mark J Ratain; Everett E Vokes; Nicholas J Vogelzang; J Anderson; B A Peterson
Laboratory and clinical studies of biochemical modulation by hydroxyurea.
Seminars in oncology 1992;19(3 Suppl 9):84-9.
1992: Mark J Ratain; Janet D Rowley
Therapy-related acute myeloid leukemia secondary to inhibitors of topoisomerase II: from the bedside to the target genes.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1992;3(2):107-11.
1992: Carole B Miller; L C Platanias; S R Mills; Marianna Zahurak; Mark J Ratain; David S Ettinger; Richard J Jones
Phase I-II trial of erythropoietin in the treatment of cisplatin-associated anemia.
Journal of the National Cancer Institute 1992;84(2):98-103.
1992: Everett E Vokes; J A Moormeier; Mark J Ratain; Merrill J Egorin; Daniel J Haraf; R Mick; Ralph R Weichselbaum
5-Fluorouracil, leucovorin, hydroxyurea, and escalating doses of continuous-infusion cisplatin with concomitant radiotherapy: a clinical and pharmacologic study.
Cancer chemotherapy and pharmacology 1992;29(3):178-84.
1992: HM Golomb; Mark J Ratain; R Mick; K Daly
The treatment of hairy cell leukemia: an update.
Leukemia 1992;6 Suppl 2():24-7.
1991: R Mick; Mark J Ratain
Modeling interpatient pharmacodynamic variability of etoposide.
Journal of the National Cancer Institute 1991;83(21):1560-4.
1991: L C Platanias; Carole B Miller; R Mick; R D Hart; Howard Ozer; J M McEvilly; Richard J Jones; Mark J Ratain
Treatment of chemotherapy-induced anemia with recombinant human erythropoietin in cancer patients.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1991;9(11):2021-6.
1991: Mark J Ratain; R Mick; F Berezin; Linda Janisch; Richard L Schilsky; Stephanie F Williams; J Smiddy
Paradoxical relationship between acetylator phenotype and amonafide toxicity.
Clinical pharmacology and therapeutics 1991;50(5 Pt 1):573-9.
1991: Mark J Ratain; R Mick; Richard L Schilsky; Nicholas J Vogelzang; F Berezin
Pharmacologically based dosing of etoposide: a means of safely increasing dose intensity.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1991;9(8):1480-6.
1991: Mark J Ratain; J Robert; W J van der Vijgh
Limited sampling models for doxorubicin pharmacokinetics.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1991;9(5):871-6.
1991: Everett E Vokes; J W Raschko; Nicholas J Vogelzang; E E Warfield; Mark J Ratain; James Doroshow; Richard L Schilsky
Five-day infusion of fluorodeoxyuridine with high-dose oral leucovorin: a phase I study.
Cancer chemotherapy and pharmacology 1991;28(1):69-73.
1991: Leonidas C Platanias; Mark J Ratain
Hairy cell leukaemia: the role of alpha interferon.
European journal of cancer (Oxford, England : 1990) 1991;27 Suppl 4():S53-7.
1990: J M Richards; R Mick; J M Latta; K Daly; Mark J Ratain; James W Vardiman; HM Golomb
Serum soluble interleukin-2 receptor is associated with clinical and pathologic disease status in hairy cell leukemia.
Blood 1990;76(10):1941-5.
1990: Mark J Ratain; Richard L Schilsky; BA Conley; Merrill J Egorin
Pharmacodynamics in cancer therapy.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1990;8(10):1739-53.
1990: Richard L Schilsky; Mark J Ratain
Clinical pharmacokinetics of high-dose leucovorin calcium after intravenous and oral administration.
Journal of the National Cancer Institute 1990;82(17):1411-5.
1990: L L Doane; Mark J Ratain; HM Golomb
Hairy cell leukemia. Current management.
Hematology/oncology clinics of North America 1990;4(2):489-502.
1989: Carolyn M Johnston; E K Senekjian; Mark J Ratain; A Talerman
Conservative management of primary cervical lymphoma using combination chemotherapy: a case report.
Gynecologic oncology 1989;35(3):391-4.
1989: J A Moormeier; Mark J Ratain; Carol A Westbrook; James W Vardiman; K M Daly; HM Golomb
Low-dose interferon alfa-2b in the treatment of hairy cell leukemia.
Journal of the National Cancer Institute 1989;81(15):1172-4.
1989: S P Ackland; Mark J Ratain; Nicholas J Vogelzang; K E Choi; M Ruane; J A Sinkule
Pharmacokinetics and pharmacodynamics of long-term continuous-infusion doxorubicin.
Clinical pharmacology and therapeutics 1989;45(4):340-7.
1989: Mark J Ratain; Richard L Schilsky; K E Choi; C Guarnieri; D Grimmer; Nicholas J Vogelzang; E Senekjian; M A Liebner
Adaptive control of etoposide administration: impact of interpatient pharmacodynamic variability.
Clinical pharmacology and therapeutics 1989;45(3):226-33.
1989: K E Choi; Mark J Ratain; Stephanie F Williams; J A Golick; J C Beschorner; L J Fullem; Jacob Bitran
Plasma pharmacokinetics of high-dose oral melphalan in patients treated with trialkylator chemotherapy and autologous bone marrow reinfusion.
Cancer research 1989;49(5):1318-21.
1989: Everett E Vokes; Richard L Schilsky; K E Choi; D M Magid; C M Guarnieri; S M Whaling; Mark J Ratain; Ralph R Weichselbaum; WR Panje
A randomized study of inpatient versus outpatient continuous infusion chemotherapy for patients with locally advanced head and neck cancer.
Cancer 1989;63(1):30-6.
1988: Mark J Ratain; James W Vardiman; C M Barker; HM Golomb
Prognostic variables in hairy cell leukemia after splenectomy as initial therapy.
Cancer 1988;62(11):2420-4.
1988: Mark J Ratain; Richard L Schilsky; B R Wojack; T Simon; E K Senekjian; Nicholas J Vogelzang
Hydroxyurea and etoposide: in vitro synergy and phase I clinical trial.
Journal of the National Cancer Institute 1988;80(17):1412-6.
1988: Mark J Ratain; HM Golomb; James W Vardiman; Carol A Westbrook; C Barker; A Hooberman; M A Bitter; K Daly
Relapse after interferon alfa-2b therapy for hairy-cell leukemia: analysis of prognostic variables.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1988;6(11):1714-21.
1988: HM Golomb; A Fefer; D W Golde; Howard Ozer; Carol S Portlock; R Silber; J Rappeport; Mark J Ratain; J Thompson; E Bonnem
Report of a multi-institutional study of 193 patients with hairy cell leukemia treated with interferon-alfa2b.
Seminars in oncology 1988;15(5 Suppl 5):7-9.
1988: James W Vardiman; Teresa A Gilewski; Mark J Ratain; M A Bitter; B A Bradlow; HM Golomb
Evaluation of Leu-M5 (CD11c) in hairy cell leukemia by the alkaline phosphatase anti-alkaline phosphatase technique.
American journal of clinical pathology 1988;90(3):250-6.
1988: B C Lembersky; Mark J Ratain; HM Golomb
Skeletal complications in hairy cell leukemia: diagnosis and therapy.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1988;6(8):1280-4.
1988: Mark J Ratain; A E Staubus; Richard L Schilsky; L Malspeis
Limited sampling models for amonafide (NSC 308847) pharmacokinetics.
Cancer research 1988;48(14):4127-30.
1988: S P Ackland; K E Choi; Mark J Ratain; Merrill J Egorin; Stephanie F Williams; J A Sinkule; Jacob Bitran
Human plasma pharmacokinetics of thiotepa following administration of high-dose thiotepa and cyclophosphamide.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1988;6(7):1192-6.
1988: HM Golomb; Mark J Ratain; A Fefer; J Thompson; D W Golde; Howard Ozer; Carol S Portlock; R Silber; J Rappeport; E Bonnem
Randomized study of the duration of treatment with interferon alfa-2B in patients with hairy cell leukemia.
Journal of the National Cancer Institute 1988;80(5):369-73.
1988: B C Lembersky; Mark J Ratain; Carol A Westbrook; HM Golomb
Rapid response to 2'-deoxycoformycin in advanced hairy cell leukemia after failure of interferons alpha and gamma.
American journal of hematology 1988;27(1):60-2.
1987: Nicholas J Vogelzang; M Ruane; Mark J Ratain; K Dhowlatshahi; G W Chodak
A programmable and implantable pumping system for systemic chemotherapy: a performance analysis in 52 patients.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1987;5(12):1968-76.
1987: Mark J Ratain; L S Kaminer; Jacob Bitran; Richard A Larson; Michelle M Le Beau; C Skosey; S Purl; Philip C Hoffman; James L Wade Iii; James W Vardiman
Acute nonlymphocytic leukemia following etoposide and cisplatin combination chemotherapy for advanced non-small-cell carcinoma of the lung.
Blood 1987;70(5):1412-7.
1987: Mark J Ratain; Nicholas J Vogelzang
Limited sampling model for vinblastine pharmacokinetics.
Cancer treatment reports 1987;71(10):935-9.
1987: E E Vokes; M A Bitter; Mark J Ratain; Michael B Prystowsky; K Daly; HM Golomb
Flow cytometry in hairy cell leukemia before and during interferon alfa-2b therapy.
Cancer 1987;59(12):1987-91.
1987: HM Golomb; A Fefer; D W Golde; Howard Ozer; Carol S Portlock; R Silber; J Rappeport; Mark J Ratain; J Thompson; E M Bonnem
Sequential evaluation of alpha-2b-interferon treatment in 128 patients with hairy cell leukemia.
Seminars in oncology 1987;14(2 Suppl 2):13-7.
1987: R G Bardawil; Mark J Ratain; HM Golomb; M A Bitter; C Groves; James W Vardiman
Changes in peripheral blood and bone marrow specimens during and after alpha 2b-interferon therapy for hairy cell leukemia.
Leukemia 1987;1(4):340-3.
1987: Mark J Ratain; HM Golomb; R G Bardawil; James W Vardiman; Carol A Westbrook; L S Kaminer; B C Lembersky; M A Bitter; K Daly
Durability of responses to interferon alfa-2b in advanced hairy cell leukemia.
Blood 1987;69(3):872-7.
1986: R G Bardawil; C Groves; Mark J Ratain; HM Golomb; James W Vardiman
Changes in peripheral blood and bone marrow specimens following therapy with recombinant alpha 2 interferon for hairy cell leukemia.
American journal of clinical pathology 1986;85(2):194-201.